Denosumab biosimilar - Jiangsu T-Mab Biopharma

Drug Profile

Denosumab biosimilar - Jiangsu T-Mab Biopharma

Alternative Names: TK-006

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu T-mab BioPharma
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Bone metastases; Postmenopausal osteoporosis

Most Recent Events

  • 03 Apr 2018 Jiangsu T-Mab Biopharma plans a phase I trial for Bone metastates (in patients with breast cancer) in China in May 2018 (NCT03487055)
  • 01 Aug 2017 Jiangsu T-mab Biopharma plans a phase I trial for postmenopausal osteoporosis in China (NCT03242512)
  • 20 Jul 2017 Phase-I clinical trials in Bone metastases in China (SC) (NCT03239756)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top